News
GPCR
40.24
+3.21%
1.25
Amgen stock rallies 13% on GLP-1 weight-loss drug update
Shares of Amgen stock rallies 13% on GLP-1 weight-loss drug update. The biotech giant expressed confidence about its GLp-1 drug candidate MariTide during its Q1 earnings call. Amgen's positive news helped push shares of its potential weight- loss drug rivals lower.
Seeking Alpha · 14m ago
Weekly Report: what happened at GPCR last week (0422-0426)?
Weekly Report · 4d ago
Baron Health Care Fund Q1 2024 Shareholder Letter
Baron Health Care Fund advanced 8.92% in the quarter ended March 31, 2024. The Fund's performance was in line with the Russell 3000 Health Care Index and the S&P 500 Index. Investments in health care equipment, pharmaceuticals, and life sciences added the most value in the period.
Seeking Alpha · 04/23 13:30
Analysts Are Bullish on These Healthcare Stocks: Corcept Therapeutics (CORT), Structure Therapeutics, Inc. Sponsored ADR (GPCR)
TipRanks · 04/23 11:20
Weekly Report: what happened at GPCR last week (0415-0419)?
Weekly Report · 04/22 12:34
13 new obesity drugs could hit the market by 2029 amid surging demand
13 new obesity drugs could hit the market by 2029 amid surging demand for the products in the U.S. World Health Organization predicts 50% of US adults will be considered obese by 2030. Sales of weight-loss drugs have soared, with Novo Nordisk and Eli Lilly generating $9.7B in 2023.
Seeking Alpha · 04/22 00:04
Structure Therapeutics Price Target Maintained With a $65.00/Share by Cantor Fitzgerald
Dow Jones · 04/18 14:03
Cantor Fitzgerald Reiterates Overweight on Structure Therapeutics, Maintains $65 Price Target
Benzinga · 04/18 13:53
Weight-loss drug developer Metsera raises $290 million in funding
Weight-loss drug developer Metsera raises $290 million in funding. The company is developing injectable and oral drugs to treat obesity. Multiple drug companies are competing to grab a slice of the weight-loss market. The market is estimated to reach $100 billion by the end of the decade.
Reuters · 04/18 11:09
Analysts Expect This 'Strong Buy' Weight-Loss Stock to Double
Structure Therapeutics (GPCR) is a clinical-stage biopharma company that went public in 2023. The company is developing a weight-loss drug that aims to treat diabetes and obesity. Cantor Fitzgerald has a price target of $65 for GPCR stock. The stock has an upside potential of 117% from current levels.
Barchart · 04/18 06:30
Weekly Report: what happened at GPCR last week (0408-0412)?
Weekly Report · 04/15 12:24
Buy Rating Affirmed for Structure Therapeutics on Upcoming GSBR-1290 Phase 2a Data Optimism
TipRanks · 04/11 04:35
Buy Rating for Structure Therapeutics on Strong Obesity Drug Prospects and Strategic Partnerships
TipRanks · 04/10 06:19
Cantor starts Structure at overweight, sees positive data for GLP-1 drug
Cantor Fitzgerald starts Structure at overweight, sees positive data for GLP-1 drug. Obesity data on GSBR-1290 is expected in Q2. Cantor is also bullish on Structure's amylin drug program for obesity. The investment firm set its price target for the stock at $65.
Seeking Alpha · 04/09 16:37
Structure Therapeutics Initiated at Overweight by Cantor Fitzgerald
Dow Jones · 04/09 11:13
Structure Therapeutics Price Target Announced at $65.00/Share by Cantor Fitzgerald
Dow Jones · 04/09 11:13
Cantor Fitzgerald Initiates Coverage On Structure Therapeutics with Overweight Rating, Announces Price Target of $65
Benzinga · 04/09 11:03
Weekly Report: what happened at GPCR last week (0401-0405)?
Weekly Report · 04/08 12:30
Weekly Report: what happened at GPCR last week (0325-0329)?
Weekly Report · 04/01 12:26
Weekly Report: what happened at GPCR last week (0318-0322)?
Weekly Report · 03/25 12:30
More
Webull provides a variety of real-time GPCR stock news. You can receive the latest news about Structure Therapeutics Inc ADR through multiple platforms. This information may help you make smarter investment decisions.
About GPCR
Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases. It is focused on G-protein coupled receptors (GPCRs) as a therapeutic target class. Its product candidates include GSBR-1290, Amylin, glucose-dependent insulinotropic polypeptide receptor (GIPR), GCGR, ANPA-0073 and LTSE-2578. It is developing GSBR-1290, its oral small molecule product candidate targeting the validated glucagon-like-peptide-1 receptor (GLP-1R) for the treatment of type 2 diabetes mellitus (T2DM) and obesity. It is developing GLP-1R candidates, including dual GLP-1R/GIPR agonists and amylin agonists, each designed with customized properties to achieve additional benefit. It is developing ANPA-0073, an investigational oral small molecule APJR agonist, for the treatment of idiopathic pulmonary fibrosis (IPF). It is evaluating its LPA1R program, LTSE-2578 for IPF and progressive pulmonary fibrosis.